ACOR - Acorda Therapeu Charts, Trade Ideas, Earnings, Ratings

ACOR - Acorda Therapeutics

$3.22 0.29[9.9%]

15 mins delayed data

People also watch : MNTA | BMRN | MYL | RGEN

+Watchlist

1 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$2.93	Open	$2.93
Volume	2.54M	Market Cap	451.17M
Yield		Last Dividend

Day

52 Week

Vanda Receives CRL From FDA for sNDA of ...	5:34 AM
Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.

Acorda Therapeutics Enters Oversold Terr...	4:44 AM
Acorda Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Kadmon (KDMN) Completes Enrollment in KD...	08/14/19
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGV...

Regeneron Ebola Treatment Shows Promise,...	08/13/19
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Ma...

Epizyme (EPZM) Q2 Loss In Line, Revenues...	08/12/19
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetosta...

Agenus (AGEN) Q2 Earnings Miss Estimates...	08/09/19
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.

Immunomedics (IMMU) Posts Wider-Than-Exp...	08/08/19
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

Horizon Therapeutics' (HZNP) Q2 Earn...	08/08/19
Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

Catalyst's (CPRX) Q2 Earnings and Re...	08/08/19
Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.

Edited Transcript of ACOR earnings confe...	08/07/19
Q2 2019 Acorda Therapeutics Inc Earnings Call

Blueprint Medicines (BPMC) Q2 Loss Widen...	08/02/19
Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

ANALYST RATINGS

4 analyst ratings (Last 6 months)

0.00 %

Strong Buy + Buy

Price Target (PT)

Hold rating	08/14/19
H.C. Wainwright downgrades from Buy to Neutral rating and lowers Price Target from $31.00 to $6.00

Hold rating	08/02/19
and lowers Price Target from $8.00 to $7.00

Hold rating	08/02/19
Stifel maintains Hold rating and lowers Price Target from $12.00 to $7.00

Hold rating	05/23/19
Wedbush initiates coverage with Neutral rating and announces Price Target of $12.00

EARNINGS

Date	2019-08-01 (BMO)	Est. (EPS/Rev.)	($1.06)/ 28.82M
Actual (EPS/Rev.)	$-0.55/ $50.05 M	EPS (TTM)	0

FINANCE

Total Revenue	$1.3B	Total Liabilities	$2.1B
Cost of Revenue	$2.5B	Total cash flow	$3.2
Total Assets	$29.98B

HOLDERS

% Insider	12.52%	% Institutional	76.43%

Top 10 Institutional Owners

Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%

TRADERS TRACKING $ACOR

No traders tracking are currently recommending this stock

SHOW ALL TRADERS

ACOR - Acorda Therapeutics

$3.22 0.29[9.9%]

Add to New List:

Day

52 Week

ANALYST RATINGS

0.00 %

Price Target (PT)

EARNINGS

FINANCE

HOLDERS

Top 10 Institutional Owners

TRADERS TRACKING $ACOR

About Us

Product Types

Strategies

Follow Us

Secure Payments